CGTLive’s Weekly Rewind – April 21, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

CGTLive takes a look at recent progress in cell therapy development targeting solid tumors, featuring expert commentary on these advances.

The investigators from Children’s Hospital of Philadelphia discussed the potential implications of their research into human adenoviruses for the development of new gene delivery tools.

The CAR-T therapy reduced disease progression risk by 74%, according to a data leak reported by STAT News. The data are expected to be presented on May 11 at the 2023 European Hematology Association Congress.

The assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed updated data on ALLO-316 in patients with ccRCC.

Infection rates in patients receiving omidubicel post-stem cell transplant were about 20% less than those in the control group.